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Both 5-ﬂuorouracil and doxorubicin are commonly used agents in chemotherapy of gastric cancer in adjuvant setting as well as
metastatic disease. In a variety of malignancies, high expression of multidrug resistance-associated protein1 and P-glycoprotein
has been associated with resistance to doxorubicin, whereas 5-ﬂuorouracil resistance has correlated with the level of
thymidylate synthase expression. We evaluated the expression of multidrug resistance-associated protein1, P-glycoprotein, and
thymidylate synthase using immunohistochemistry in 103 locally advanced gastric cancer patients (stage IB-IV) who underwent
5-ﬂuorouracil and doxorubicin-based adjuvant chemotherapy after curative resection and investigated the association between
their expression and clinicopathologic characteristics including prognosis of the patients. While high expression (55% of
tumour cells positive) of multidrug resistance-associated protein1 and P-glycoprotein was observed in 70 patients (68%) and
42 patients (41%), respectively, 65 patients (63%) had primary tumours with high expression (525% of tumour cells positive)
of thymidylate synthase. There was a signiﬁcant association between multidrug resistance-associated protein1 and P-
glycoprotein expression (P50.0001) as well as P-glycoprotein and thymidylate synthase expression (P50.0001). High
multidrug resistance-associated protein1 and P-glycoprotein expressions were associated with well and moderately
differentiated histology (P50.0001 and P=0.03, respectively) and intestinal type (P50.0001 and P=0.009, respectively).
High multidrug resistance-associated protein1 expression correlated with lymph node metastasis (P=0.037), advanced stage
(P=0.015), and older age (P=0.021). Five-year disease-free survival and overall survival of total patients were 55.2% and 56.2%,
respectively, with a median follow-up of 68 months. There were no signiﬁcant differences in disease-free survival and overall
survival according to the expression of multidrug resistance-associated protein1 (P=0.902 and P=0.975, respectively), P-
glycoprotein (P=0.987 and P=0.955, respectively), and thymidylate synthase (P=0.604 and P=0.802, respectively). Concurrent
high expression of these proteins (high multidrug resistance-associated protein1/P-glycoprotein, high multidrug resistance-
associated protein1/thymidylate synthase, high P-glycoprotein/thymidylate synthase) did not correlate with disease-free survival
or overall survival. Even high expression of all three proteins was not associated with poor disease-free survival (P=0.919) and
overall survival (P=0.852). In conclusion, high expression of multidrug resistance-associated protein1, P-glycoprotein, and
thymidylate synthase did not predict poor prognosis of gastric cancer patients treated with 5-ﬂuorouracil and doxorubicin-
based adjuvant chemotherapy. A larger study including patients treated with surgical resection alone would be necessary.
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Gastric cancer is the most common malignancy in many countries
including Korea (Fuchs and Mayer, 1995; Suh et al, 2000). The
prognosis of patients with locally advanced gastric cancer is gener-
ally poor even with curative resection, which is an essential
treatment for the long-term survival of patients (Noguchi et al,
1989; Fuchs and Mayer, 1995). Adjuvant chemotherapy has failed
to demonstrate a signiﬁcant survival beneﬁt for such patients in
most randomized trials and meta-analyses although a recent study
showed improved survival with postoperative chemoradiotherapy
compared to surgery alone (Krook et al, 1991; Hermans et al,
1993; Fuchs and Mayer, 1995; Lise et al, 1995; Macdonald et al,
1995; Kelsen, 1996; Kim et al, 1998; Cirera et al, 1999; Earle and
Maroun, 1999; Macdonald et al, 2001).
In adjuvant chemotherapy of gastric cancer, 5-ﬂuorouracil (5-
FU) and doxorubicin have been commonly used in combination
(Krook et al, 1991; Hermans et al, 1993; Lise et al, 1995; Macdo-
nald et al, 1995; Kelsen, 1996; Kim et al, 1998; Earle and
Maroun, 1999). Since the intrinsic or acquired resistance of cancer
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www.bjcancer.comcells to these agents is the most important cause of the failure of
adjuvant chemotherapy, identiﬁcation of molecules associated with
the resistance of tumours to anticancer drugs can provide valuable
information in adjuvant chemotherapy of gastric cancer.
In terms of resistance to 5-FU, thymidylate synthase (TS), which
is a critical target of 5-FU, has been widely investigated. TS cata-
lyses the methylation of deoxyuridine monophosphate to
deoxythymidine monophosphate, which is an essential process for
DNA synthesis (Pinedo and Peters, 1988). High expression of TS
may be associated with 5-FU resistance in a variety of malignancies
including gastric cancer (Johnston et al, 1992, 1995; Lenz et al,
1996). For doxorubicin, multidrug resistance (MDR), which means
the resistance of cancer cells against several anticancer drugs, has
been considered as one of the important causes of drug resistance
(Goldstein et al, 1989; Gottesman and Pastan, 1993). The best-
characterised mechanism of MDR is overexpression of P-glycopro-
tein (P-gp) encoded by MDR1 gene (Goldstein et al, 1989;
Gottesman and Pastan, 1993). P-gp is 170-Kda transmembrane
protein and functions as an adenosine triphosphate-dependent
drug efﬂux pump (Goldstein et al, 1989; Gottesman and Pastan,
1993). It is responsible for resistance of cancer cells to a wide range
of structurally unrelated cytotoxic agents including doxorubicin,
etoposide, vinca alkaloid, and actinomycin-D (Goldstein et al,
1989; Gottesman and Pastan, 1993). In addition to P-gp, multidrug
resistance-associated protein1 (MRP1), 190-Kda membrane bound
glycoprotein encoded by MRP1 gene, has been found to be
involved in the resistance of cancer cells to the same category of
anticancer drugs as in P-gp with similar mechanism (Cole et al,
1992; Hipfner et al, 1999). Moreover, MRP1 expression has been
associated with resistance to chemotherapeutic agents or poor
survival in breast cancer, neuroblastoma, lung cancer, and gastric
cancer (Endo et al, 1996a,b; Norris et al, 1996; Nooter et al,
1997; Young et al, 1999).
In gastric cancer patients who underwent surgical resection with
or without adjuvant chemotherapy, several investigators have
reported the prognostic signiﬁcance of TS, MRP1, and P-gp with
conﬂicting results (Endo et al, 1996a; Monden et al, 1997; Kuniya-
su et al, 1998; Takebayashi et al; 1998; Suda et al, 1999; Choi et al,
2001). We have recently reported that expression of TS did not
predict poor survival in 103 gastric cancer patients treated with
5-FU and doxorubicin-based adjuvant chemotherapy after curative
resection (Choi et al, 2001). We evaluated the expression of MRP1,
P-gp, and TS using the same cohort with longer follow-up and
investigated the association between their expression and various
clinicopathologic characteristics including prognosis of the patients.
MATERIALS AND METHODS
Patients
Included in this study were 103 patients with locally advanced
gastric adenocarcinoma who underwent 5-FU and doxorubicin-
based adjuvant chemotherapy after curative surgical resection at
Ajou University Medical Center in Suwon, Korea, between July
1994 and October 1996. All patients had a postsurgical pathologic
stage ranging from IB to IV without evidence of distant metastasis
according to the American Joint Committee on Cancer (1997)
TNM classiﬁcation. Patients with distant abdominal lymph node
metastasis (M1) were excluded.
In terms of adjuvant chemotherapy, the most commonly admi-
nistered regimen was FA (5-FU, doxorubicin) with OK-432 (51
patients), followed by FAM (5-FU, doxorubicin, mitomycin-C)
(33 patients), FA (11 patients), and FA with lentinan (eight
patients). Chemotherapy was usually started 2–3 weeks after
surgery. In FA regimen with or without immunotherapy (OK-
432 or lentinan), 5-FU (500 mg m
72 per day) was given by intra-
venous (i.v.) infusion for 30 min on days 1, 8 and 15, and
doxorubicin (40 mg m
72) was given by rapid i.v. injection on
day 1. The treatment was repeated every 3 weeks for 12 cycles.
OK-432 (2.0 Klinishe Einheit/day) and lentinan (2 mg/day) were
administered intramuscularly and intravenously, respectively,
weekly throughout the FA chemotherapy period. In FAM regimen,
5-FU (1000 mg m
72 per day) was given by continuous i.v. infu-
sion on days 1 to 3, and doxorubicin (40 mg m
72) and
mitomycin-C (10 mg m
72, every other cycle) were administered
by rapid i.v. injection on day 1. The treatment was repeated every
4 weeks for 12 cycles and mitomycin-C was administered every 8
weeks. The other characteristics of patients including the deﬁnition
of curative section and follow-up schedule after treatment were
previously described (Choi et al, 2001).
Immunohistochemical staining
Immunohistochemical staining of formalin-ﬁxed, parafﬁn-
embedded tumour tissue was performed using MRPr1 monoclonal
antibody against MRP1 (Signet Laboratories, Dedham, MA, USA),
JSB-1 monoclonal antibody against P-gp (Signet Laboratories,
Dedham, MA, USA), and TS 106 monoclonal antibody against
TS (Neomarkers, Fremont, CA, USA) as described previously (Choi
et al, 2001).
Formalin-ﬁxed, parafﬁn-embedded sections of colon adenocarci-
noma known to have high expression of TS and normal colon
tissue were used as positive controls for TS and P-gp, respectively.
The negative controls for TS and P-gp were made by the omission
of the primary antibody during the process of immunohistochem-
ical staining. For MRP1, cytospin preparation of the MRP1-
overexpressing doxorubicin-resistant human lung cancer cell line
GLC4/ADR and its drug-sensitive parental cell line GLC4, which
were kindly provided by Dr EG de Vries (Groningen University,
Groningen, The Netherlands), were used as positive and negative
control, respectively.
Tissue evaluation
The slides were examined independently by two observers (H.J.J.
and K.B.L) blinded to both clinical and pathologic data. The
expression of TS was divided into high TS (greater than or equal
to 25% of tumour cells positive) and low TS (less than 25% of
tumour cells positive or no staining) groups as reported previously
(Choi et al, 2001). The expression of MRP1 and P-gp was also clas-
siﬁed into high (greater than or equal to 5% of tumour cells
positive) and low (less than 5% of tumour cells positive or no
staining) based on the extent of staining.
Statistical analysis
Disease-free survival (DFS) and overall survival (OS) were calcu-
lated using Kaplan–Meier Method (Kaplan and Meier, 1958).
Disease-free survival was deﬁned as the time from the day of
operation to a documented recurrence, or second primary cancer,
or death from any other cause. Data on patients who did not have
a recurrence were censored at the last follow-up. Overall survival
was deﬁned as the time from the day of operation to death; data
on survivors were censored at the last follow-up. The differences
between the survival curves were tested by using the log-rank test.
Comparison of variables according to the expression of drug-resis-
tance proteins was evaluated with the Student’s t-test and chi-
square test.
RESULTS
Patient characteristics
Of 103 patients who were assessable to drug resistance proteins, 71
were male and 32 were female, and their median age was 53 years
(range, 28 to 72). Stages were IB in 9, II in 28, IIIA in 31, IIIB in
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cycles was 8 (range, 1 to 13).
Association of expression of drug resistance proteins with
patient and tumour characteristics
TS staining pattern in gastric tumours and typical examples were
previously reported (Choi et al, 2001). Within the study group,
65 patients (63%) had primary tumours with high TS expression
(525% of tumor cells positive), and 38 patients (37%) demon-
strated low TS expression (525% of tumour cells positive or no
staining). The relationship between TS expression and patient
and tumour characteristics was also previously reported (Choi et
al, 2001). High TS expression was associated with poorly differen-
tiated histology (P=0.015) and mixed type tumours in Lauren’s
classiﬁcation (P=0.027).
Both MRP1 and P-gp staining pattern in gastric tumours
showed predominantly cytoplasmic staining in tumour cells
(Figure 1). High expression (55% of tumour cells positive) of
MRP1 and P-gp in primary tumour was observed in 70 patients
(68%) and 42 patients (41%), respectively. High MRP1 and P-
gp expression were associated with well and moderately differen-
tiated histology (P50.0001 and P=0.03, respectively) and
intestinal type (P50.0001 and P=0.009, respectively). High
MRP1 expression correlated with lymph node metastasis
(P=0.037), advanced stage (P=0.015), and older age (P=0.021).
There was no signiﬁcant association between expression of
MRP1 and P-gp and other patient and tumour characteristics
(Table 1). MRP1 and P-gp expressions were signiﬁcantly asso-
ciated with each other (P50.0001) (Table 2). There was also
signiﬁcant association between P-gp and TS expression
(P50.0001) (Table 2). Multidrug resistance-associated protein1
and TS did not correlate with each other (P=0.094).
Association of expression of drug resistance proteins with
outcome of patients
The median follow-up duration of the survivors was 68 months
(range: 53–80 months) and no patient was lost to follow-up. At
the time of analysis, 40 patients had recurrences, and two had
second primary cancer (hepatocellular carcinoma and laryngeal
cancer, respectively). Forty-seven of the 103 patients have died.
Death due to recurrence of gastric cancer occurred in 40 patients.
Two patients died of gastrointestinal bleeding and pneumonia,
respectively, without evidence of recurrence, one patient died of
second primary cancer (hepatocellular carcinoma), and the causes
of death were undetermined in four patients.
Five-year DFS and OS of total patients were 55.2% and 56.2%,
respectively. There were no signiﬁcant differences in DFS and OS
according to the expression of MRP1 (P=0.902 and P=0.975,
respectively), P-gp (P=0.987 and P=0.955, respectively), and TS
(P=0.604 and P=0.802, respectively) (Figures 2–4). Concurrent
high expression of these proteins (high MRP1 and P-gp, high
MRP1 and TS, high P-gp and TS) did not correlate with DFS or
OS (Table 3). Even high expression of all three proteins was not
associated with poor DFS (P=0.919) and OS (P=0.852) (Table
3). The prognostic signiﬁcance of other clinicopathologic charac-
teristics was previously reported (Choi et al, 2001). There were
no signiﬁcant differences in DFS and OS according to other char-
acteristics except size (P=0.024 and P=0.017, respectively) and
location (P=0.019 and P=0.027, respectively) of primary tumour
with extended follow-up of patients.
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Figure 1 Immunohistochemical staining of MRP1 and P-gp in gastric cancer. (A) Tubular adenocarcinoma showing strong immunoreactivity for MRP1
compared to normal foveolar epithelium (6100). (B) Signet ring cell carcinoma showing strong cytoplasmic staining of MRP1 compared to non-neoplastic
epithelium (6200). (C) Tubulopapillary adenocarcinoma showing diffuse immunoreactivity for P-gp (6200). (D) Strong expression of P-gp in cytoplasm of
tubular adenocarcinoma (6200).
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Table 1 Characteristics of patients according to MRP1 and P-gp expression
a
MRP1 P-gp
Characteristics Low High P value Low High P value
Age 49.1+10.4 53.7+8.8 0.021 50.8+9.1 54.2+10.0 0.072
Gender 0.210 0.079
Male 20 (61) 51 (73) 39 (62) 33 (79)
Female 13 (39) 19 (27) 23 (38) 9 (21)
Type of operation 0.091 0.758
Subtotal 18 (55) 50 (71) 41 (67) 27 (64)
Total 15 (45) 20 (29) 20 (33) 15 (36)
Primary tumour size (cm) 5.4+3.4 6.1+2.5 0.245 5.9+3.1 5.9+2.4 0.921
Tumour location 0.190 0.064
Lower 17 (52) 38 (54) 35 (57) 20 (48)
Mid 8 (24) 25 (36) 14 (23) 19 (45)
Upper 7 (21) 5 (7) 10 (16) 2 (5)
Diffuse 1 (3) 2 (3) 2 (3) 1 (2)
Borrmann type 0.099 0.067
I 0 (0) 6 (9) 2 (3) 4 (10)
II 9 (27) 14 (20) 18 (30) 5 (12)
III 18 (55) 45 (64) 33 (54) 30 (71)
IV 6 (18) 5 (7) 8 (13) 3 (7)
Tumour differentiation 50.0001 0.030
Well 0 (0) 13 (19) 5 (8) 8 (19)
Moderate 4 (12) 27 (39) 13 (21) 18 (43)
Poor 16 (49) 21 (30) 26 (43) 11 (26)
Signet ring 11 (33) 6 (9) 12 (20) 5 (12)
Undifferentiated 0 (0) 1 (1) 1 (2) 0 (0)
Mucinous 2 (6) 2 (3) 4 (7) 0 (0)
Lauren’s classiﬁcation 50.0001 0.009
Intestinal 9 (27) 48 (69) 30 (49) 27 (64)
Diffuse 9 (27) 3 (4) 12 (20) 0 (0)
Mixed 15 (46) 19 (27) 19 (31) 15 (36)
Lymphatic invasion 0.327 0.577
Yes 23 (70) 55 (79) 45 (74) 33 (79)
No 10 (30) 15 (21) 16 (26) 9 (21)
Depth of tumour invasion 0.821 0.635
T2 12 (36) 30 (43) 27 (44) 15 (36)
T3 20 (61) 38 (54) 32 (53) 26 (62)
T4 1 (3) 2 (3) 2 (3) 1 (2)
Lymph node involvement 0.037 0.071
N0 4 (12) 14 (20) 8 (13) 10 (24)
N1 18 (55) 23 (33) 28 (46) 13 (31)
N2 10 (30) 18 (26) 19 (31) 9 (21)
N3 1 (3) 15 (21) 6 (10) 10 (24)
Stage 0.015 0.251
IB 0 (0) 9 (13) 4 (7) 5 (12)
II 13 (39) 15 (21) 16 (26) 12 (29)
IIIA 10 (30) 21 (30) 23 (38) 8 (19)
IIIB 8 (24) 9 (13) 10 (16) 7 (17)
IV 2 (6) 16 (23) 8 (13) 10 (24)
Chemotherapy 0.833 0.691
FA+OK-432
b 18 (55) 33 (47) 31 (51) 20 (48)
FAM
b 9 (27) 24 (34) 18 (30) 15 (36)
FA 4 (12) 7 (10) 8 (13) 3 (7)
FA+lentinan 2 (6) 6 (9) 4 (7) 4 (10)
Cycles of chemotherapy 8.4+3.3 8.5+3.7 0.813 8.2+3.5 9.0+3.6 0.248
aValues are number or mean+standard deviation, with percentages in parentheses.
bF, 5-FU; A, doxorubicin;
M, mitomycin-C.
Table 2 Correlation of expression between MRP1 and P-gp, TS and P-gp
Expression of MRP1 Expression of TS
Expression of P-gp Low High P value Low High P value
Low 29 (88%) 32 (46%) 50.0001 32 (84%) 29 (45%) 50.0001
High 4 (12%) 38 (54%) 6 (16%) 36 (55%)
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In this study, we evaluated the clinical signiﬁcance of MRP1, P-gp,
and TS known to be associated with resistance of tumours to 5-FU
and doxorubicin in locally advanced gastric cancer patients treated
with 5-FU and doxorubicin-based adjuvant chemotherapy after
curative resection. The association between TS expression and clin-
icopathologic characteristics was previously reported (Choi et al,
2001).
In terms of MRP1 expression in primary tumours, 68% of
tumours demonstrated high expression of MRP1. According to
other studies, MRP1 expression was reported in 34–55% of
patients with gastric cancer (Endo et al, 1996a,b; Takebayashi et
al, 1998; Alexander et al, 1999). Multidrug resistance-associated
protein1 expression was associated with well and moderately differ-
entiated histology and intestinal type, which was compatible with
previous reports (Takebayashi et al, 1998; Alexander et al, 1999).
Furthermore, a signiﬁcant correlation was found between MRP1
expression and advanced stage. While there was no report showing
such relationship in gastric cancer, a study demonstrated a signiﬁ-
cant association between high expression of MRP1 and advanced
stage in breast cancer suggesting the role of MRP1 as a marker
of aggressive tumour behaviour (Filipits et al, 1996). The mean
age of patients with high MRP1 expression was higher than that
of patients with low MRP1. This result has relevance to a higher
proportion of intestinal type carcinoma, which occurs more often
in old patients, in high MRP1 group compared to low MRP1
group (Fuchs and Mayer, 1995). Furthermore, patients with intest-
inal type tumour showed a higher mean age compared to those
with diffuse type in the present study (data not shown).
High expression of P-gp was observed in 41% and also asso-
ciated with well and moderately differentiated histology and
intestinal type as in MRP1. Similar proportion of high expression
of P-gp and correlation with well differentiated tumour have been
reported in other studies (Mizoguchi et al, 1990; Fujii et al, 1995;
Monden et al, 1997; Motoo et al, 1998). One interesting ﬁnding
was a strong association between MRP1 and P-gp expression.
While two studies showed no signiﬁcant correlation between
MRP1 and P-gp in gastric cancer, conﬂicting results were reported
in breast cancer (Filipits et al, 1996; Beck et al, 1998; Dexter et al,
1998; Alexander et al, 1999; Fan et al, 2000; Ferrero et al, 2000).
The present study suggests that both MRP1 and P-gp are
frequently expressed in well and moderately differentiated and
intestinal type gastric cancer and closely associated with each other.
There is a possibility that MRP1 and MDR1 gene may be coordi-
nately regulated in gastric cancer tissue. There was also a signiﬁcant
correlation between P-gp and TS expression. It is an unexpected
ﬁnding and further studies would be necessary to ﬁnd a possible
explanation for such a result.
In gastric cancer, the prognostic signiﬁcance of TS, MRP1, and
P-gp expression has been showing conﬂicting results (Endo et al,
1996a; Monden et al, 1997; Kuniyasu et al, 1998; Takebayashi et
al; 1998; Suda et al, 1999; Choi et al, 2001). While TS expression
predicted increased risk of recurrence and poor survival in
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Figure 2 Disease-free survival (A) and overall survival (B) of gastric can-
cer patients according to MRP1 expression.
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Figure 3 Disease-free survival (A) and overall survival (B) of gastric can-
cer patients according to P-gp expression.
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tion in two studies, our previous study showed no signiﬁcant
differences in DFS and OS between high TS and low TS group
(Kuniyasu et al, 1998; Suda et al, 1999; Choi et al, 2001). There
are two studies that investigated the association between MRP1
expression and survival of patients treated with surgery, which
failed to demonstrate the prognostic signiﬁcance of MRP1 expres-
sion (Endo et al, 1996a; Takebayashi et al; 1998). On the other
hand, a study suggested that high expression of P-gp was poor
prognostic factor in gastric cancer patients who underwent surgi-
cal resection followed by adjuvant chemotherapy (Monden et al,
1997).
There were no signiﬁcant differences in DFS and OS of gastric
cancer patients according to the expression of MRP1, P-gp, and
TS in the present study. We also investigated the prognostic
signiﬁcance of concurrent expression of these three drug resis-
tance proteins. However, concurrent expression of drug
resistance proteins did not predict increased recurrence or poor
survival. Even high expression of all three proteins was not asso-
ciated with poor prognosis. These results are a somewhat
unexpected ﬁnd considering the fact that we simultaneously
investigated the clinical relevance of well-established drug resis-
tance proteins, which are known to be involved in resistance
of tumours to 5-FU and doxorubicin. The lack of prognostic
implication of TS, MRP1, and P-gp expression in gastric cancer
patients who underwent adjuvant chemotherapy could be
explained as follows. The expression of these drug resistance
proteins in primary tumours of gastric cancer patients may not
reﬂect the drug resistance of microresidual or micrometastatic
cancer cells which cause the recurrence (Choi et al, 2001). There
is also a possibility that the gastric cancer patients with high
expression of drug resistance proteins might experience greater
survival beneﬁt from adjuvant chemotherapy compared to
patients with low expression as shown in other studies that
investigated the expression of TS in rectal cancer and breast
cancer (Johnston et al, 1994; Pestalozzi et al, 1997). However,
a larger study including patients treated with surgical resection
alone would be essential to clearly deﬁne the prognostic implica-
tion of these drug resistance proteins in adjuvant chemotherapy
of gastric cancer.
To our knowledge, the present study is the ﬁrst report that
investigated the expression of TS, MRP1, and P-gp simultaneously
in gastric cancer patients who underwent 5-FU and doxorubicin-
based adjuvant chemotherapy. In other studies that investigated
the clinical relevance of MRP1 or P-gp, the patients usually
received ﬂuoropyrimidine with or without mitomycin-C, in which
neither MRP1 nor P-gp is associated with drug resistance (Gold-
stein et al, 1989; Cole et al, 1992; Gottesman and Pastan, 1993;
Endo et al, 1996a; Monden et al, 1997; Hipfner et al, 1999). Our
results suggest the possibility that the expression of drug resis-
tance-related proteins has little clinical signiﬁcance in gastric
cancer patients who received adjuvant chemotherapy. Similarly, a
study that investigated the expression of MRP1 and MDR1 mRNA
simultaneously in node-positive breast cancer patients who
received anthracycline-based adjuvant chemotherapy, expression
of MRP1 and MDR1 had no signiﬁcant inﬂuence on survival
(Ferrero et al, 2000).
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Figure 4 Disease-free survival (A) and overall survival (B) of gastric can-
cer patients according to TS expression.
Table 3 Disease-free and overall survival of the patients according to the concurrent expression of drug resistance proteins
Characteristics No. of Patients 5-year disease-free survival (%) P value 5-year overall survival (%) P value
MRP1 and P-gp 0.756 0.704
Both high 38 52.5 52.5
Others 65 56.8 58.3
MRP1 and TS 0.711 0.840
Both high 48 56.2 56.2
Others 55 54.4 56.2
P-gp and TS 0.818 0.886
Both high 36 55.4 55.4
Others 67 55.1 56.6
MRP1 and P-gp and TS 0.919 0.852
All high 32 52.9 52.9
Others 71 56.2 57.6
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1578–1585In conclusion, high expression of MRP1, P-gp, and TS including
concurrent expression did not predict poor DFS and OS in patients
with locally advanced gastric cancer treated with 5-FU and doxor-
ubicin-based chemotherapy after curative resection. A larger study
including patients treated with surgical resection alone would be
necessary.
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